Emd Serono Patent-Cliff Exposure & CMS Drug Spending Portfolio
Emd Serono (US): 10 reconciled FDA prescription therapies (6.8% 2025 to 2030 cliff risk), $619.0M 2024 CMS Part D & Medicaid spend, and 90 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 10 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 6.8% |
| Primary Portfolio LOE Date | 2030-01-01 |
| 2024 CMS Total Public Spend | $619.0M |
| 2024 Medicare Part D Spend | $504.1M |
| 2024 Medicaid Spend | $114.9M |
| California HCAI SB 17 Filings | 90 WAC filings (max 23.9% 2-yr change) |